Astellas Pharma Inc
F:YPHA
Astellas Pharma Inc
F:YPHA
Price:
13.4
EUR
-0.74%
Market Closed
Market Cap:
€24B
Relative Value
The Relative Value of one
YPHA
stock under the Base Case scenario is
11.89
EUR.
Compared to the current market price of 13.4 EUR,
Astellas Pharma Inc
is
Overvalued by 11%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
YPHA
Relative Value
Base Case
11.89
EUR
Overvaluation 11%
Multiples Across Competitors
YPHA Competitors Multiples
Astellas Pharma Inc Competitors
Astellas Pharma Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| JP |
|
Astellas Pharma Inc
F:YPHA
|
4.7T EUR | 2.3 | 14.4 | 8 | 11.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
987.9B USD | 15.2 | 47.9 | 32.3 | 34.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
596.5B USD | 6.3 | 22.3 | 15.4 | 19 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
293B CHF | 4.8 | 31.2 | 13.1 | 15.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
249.7B CHF | 5.7 | 23 | 14.2 | 18.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
240.5B GBP | 5.5 | 31.7 | 17.5 | 24.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
307.4B USD | 4.7 | 16.8 | 10.5 | 12.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.4 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.9B USD | 2.5 | 20.2 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD | 2.6 | 17.8 | 7.4 | 9.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
